Biotech News

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics (ARQT)Arcutis Biotherapeutics2026-08-05 20:00 ESTEarnings

Continued strong ZORYVE ® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand growth Company raising 2026 full-year net product sales guidance to $525 million–$540 million Received

Arcutis Biotherapeutics

Medical Dermatology Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology. ZORYVE Franchise ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic...

Recent company news

ARQTArcutis Biotherapeutics2026-08-07 20:00 EST

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Stock data

Close: 26.43 USD
Market cap: 2.6B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Related news

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics

Recent company news

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)